<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02917291</url>
  </required_header>
  <id_info>
    <org_study_id>FAB117-CT-01</org_study_id>
    <nct_id>NCT02917291</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury</brief_title>
  <acronym>SPINE</acronym>
  <official_title>Clinical Trial of Phase 1/2 to Evaluate the Feasibility, Safety, Tolerability and Preliminary Efficacy of the Administration of FAB117-HC, a Drug Whose Active Ingredient is HC016, Allogeneic Adipose Derived Adult Mesenchymal Stem Cells Expanded and Pulsed With H2O2, in Acute Traumatic SCI Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferrer Internacional S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Histocell, S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ferrer Internacional S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is the evaluation of the safety and tolerability of FAB117-HC&#xD;
      (a medicinal product containing human allogeneic adipose derived adult mesenchymal stem cells&#xD;
      expanded and pulsed with H2O2, HC016 cells) administered at a single-time point to patients&#xD;
      with acute thoracic traumatic spinal cord injury (SCI). The study will also include initial&#xD;
      exploration of potential clinical efficacy. Dose levels of 20 million and 40 million cells&#xD;
      will be administered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FAB117-HC is an investigational medicinal product whose active substance is HC016, allogeneic&#xD;
      adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2.&#xD;
&#xD;
      The main purpose of this study is to evaluate the safety and tolerability of a single&#xD;
      administration of FAB117-HC using: a) two sequential escalating doses administered between 72&#xD;
      and 120 hours post-injury, to patients with acute traumatic SCI with ASIA Impairment Scale&#xD;
      (AIS) grade A; and b) the determined maximum tolerated dose administered up to 96 h&#xD;
      post-injury to patients with AIS grading of A or B. The study includes also initial&#xD;
      exploration of efficacy.&#xD;
&#xD;
      Treatment is administered by intramedullary injection into the injured spinal cord, during&#xD;
      the decompression and stabilization surgery (DSS) of the fracture. DSS is routinely performed&#xD;
      on almost all SCI patients.&#xD;
&#xD;
      The study has been divided into two phases:&#xD;
&#xD;
      Phase 1 (open label): 8 AIS A patients with lesion located between D1 and D12 will be&#xD;
      included in 2 sequential cohorts.&#xD;
&#xD;
      Phase 2 (randomized, controlled, double-blind): Up to 40 AIS A or B patients with lesion&#xD;
      located between D1 and D12, will be randomly divided into two groups (control and treated)&#xD;
      that will be balanced in AIS grade.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events as a measure of safety and tolerability of a single dose of FAB117-HC when administered by intramedullary injection into the injured spinal cord</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in neurological function using the International Standards for Neurological Classification of SCI (ISNCSCI) scale, examinations at 24h, 72h, 7d, 14d, 28d, 90d and 360 days after injection of FAB117-HC</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the functional assessment of Spinal Cord Independence Measure (SCIM III)</measure>
    <time_frame>Day 28 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Somatosensory-Evoked Potentials (SSEP) electrophysiological assessment test.</measure>
    <time_frame>Day 28 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Motor-Evoked Potentials (MEP) electrophysiological assessment test</measure>
    <time_frame>Day 28 and Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Acute Traumatic Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>FAB117-HC (Ph 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with acute traumatic spinal cord injury grading AIS A (8 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (Ph 2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FAB117-HC (Ph 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FAB117-HC</intervention_name>
    <description>(Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells)</description>
    <arm_group_label>FAB117-HC (Ph 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>(Ph 2) No treatment will be administered</description>
    <arm_group_label>Control group (Ph 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FAB117-HC</intervention_name>
    <description>(Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)</description>
    <arm_group_label>FAB117-HC (Ph 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase 1 (2 Cohorts)&#xD;
&#xD;
          1. Male or female subjects ≥ 16 to ≤ 70 years.&#xD;
&#xD;
          2. ASIA impairment grade A.&#xD;
&#xD;
          3. Either a level of injury between D1-D12 both inclusive (cohorts 1 and 2).&#xD;
&#xD;
          4. Single traumatic spinal cord injury as defined by MRI.&#xD;
&#xD;
          5. Injury occurred between 72 and 120h before undergoing DSS and treatment.&#xD;
&#xD;
          6. Clinically and haemodynamically stable, under medical criteria, enough to undergo DSS.&#xD;
&#xD;
          7. Able to give informed consent either in writing or orally in the presence of a&#xD;
             witness.&#xD;
&#xD;
        Phase 2 (2 Groups)&#xD;
&#xD;
          1. Male or female subjects ≥ 16 to ≤ 70 years.&#xD;
&#xD;
          2. ASIA impairment grade A or B.&#xD;
&#xD;
          3. An injury between D1 and D12, both inclusive.&#xD;
&#xD;
          4. Single traumatic spinal cord injury as defined by MRI.&#xD;
&#xD;
          5. Injury occurring up to 96 h before undergoing DSS and treatment.&#xD;
&#xD;
          6. Clinically and haemodynamically stable enough, under medical criteria, to undergo DSS.&#xD;
&#xD;
          7. Able to give informed consent either in writing or orally in the presence of a&#xD;
             witness.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participated in a previous clinical study and received an investigational product&#xD;
             within 28 days of SCI (within 5 years of SCI if the investigational product is a&#xD;
             cell-based medicine).&#xD;
&#xD;
          2. Radiological or MRI or DSS evidence of complete or partial spinal cord transection.&#xD;
&#xD;
          3. Inability to unequivocally identify the injection sites.&#xD;
&#xD;
          4. Multiple injuries to the neurological spinal cord at different levels.&#xD;
&#xD;
          5. Patients with any of these additional conditions:&#xD;
&#xD;
               1. Penetrating spinal cord injuries.&#xD;
&#xD;
               2. Associated trauma or injury to the brachial and / or lumbosacral plexus.&#xD;
&#xD;
          6. Active infection in the surgical area.&#xD;
&#xD;
          7. Haemodynamic instability contraindicating DSS procedure in the time frame defined for&#xD;
             inclusion in the trial.&#xD;
&#xD;
          8. Multiple organ failure.&#xD;
&#xD;
          9. Severe multiple trauma that hampers the stabilization procedure in the defined term&#xD;
             for the inclusion in the trial.&#xD;
&#xD;
         10. Significant head injury (Score on the Glasgow scale less than or equal to 13 and / or&#xD;
             abnormal MRI/CT, meaning oedema, axonal lesion and/or haemorrhage) or other injury&#xD;
             that in the investigator's opinion is sufficient to interfere with the assessment of&#xD;
             spinal cord function or compromise the validity of patient data.&#xD;
&#xD;
         11. Patients undergoing mechanical ventilation that does not allow a prior clinical&#xD;
             examination.&#xD;
&#xD;
         12. Inability to communicate with the neurological examiner so that the validity of&#xD;
             patient data could be unreliable.&#xD;
&#xD;
         13. Coma or significant impairment in the level of consciousness, including&#xD;
             unconsciousness due to sedative-analgesic medications, that interferes with the&#xD;
             performance or interpretation of assessments specific in the protocol.&#xD;
&#xD;
         14. Preexisting or current significant diseases such as hepatitis C, HIV, epilepsy,&#xD;
             neoplastic disease or other diseases that could cause neurological deficits including&#xD;
             syphilis, myelopathy, and polyneuropathy.&#xD;
&#xD;
         15. Background or acute episode of Guillain-Barre syndrome.&#xD;
&#xD;
         16. History of meningitis or meningoencephalitis.&#xD;
&#xD;
         17. Current autoimmune disease treated with immunosuppressant therapy.&#xD;
&#xD;
         18. Patients with history of severe thrombophilia or under anticoagulant pharmacological&#xD;
             therapy which long elimination half-live prevents a rapid transition to heparin (like&#xD;
             dabigatran and rivaroxaban).&#xD;
&#xD;
         19. Presence of any psychiatric illness, as defined by the DSM-IV-TR, or medically&#xD;
             unstable illness that means a hindrance to the adherence to rehabilitation and/or to&#xD;
             the informed consent signature.&#xD;
&#xD;
         20. Pregnant women or women of childbearing age who are not using an appropriate method of&#xD;
             contraception and, moreover, are not willing to continue to use it for the duration of&#xD;
             the trial. If the patient is menopausal or sterile, it must be documented in the&#xD;
             medical record.&#xD;
&#xD;
         21. Women who are breastfeeding if unwilling to stop at the time of recruitment.&#xD;
&#xD;
         22. History of allergy with anaphylactic shock.&#xD;
&#xD;
         23. Patients with known hypersensitivity to any of the excipients of FAB117-HC.&#xD;
&#xD;
         24. Patients with known hypersensitivity to penicillin, streptomycin, enzymes (trypsin or&#xD;
             collagenase), bovine serum or DMSO.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrés G Fernández, PhD</last_name>
    <email>ferreradvancedbiotherapeutics@ferrer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Rodríguez Sotillo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miguel Ángel González Viejo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Inmaculada García Montes, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Igor Paredes Sansinenea, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juana María Barrera Chacón, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Toledo (HNP y VS)</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ángel Gil Agudo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Teresa Bas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabel Villarreal, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Begoña Hidalgo, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trauma Spinal Cord</keyword>
  <keyword>Thoracic Acute Spinal Cord Injury</keyword>
  <keyword>Neurosurgery</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>ATMP</keyword>
  <keyword>HC016 adipose mesenchymal stem cell</keyword>
  <keyword>SPINE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

